De Velasco et al. [37], in their meta-analysis, reported a higher risk of all-grade rash (3.94 vs. 1.59, p = 0.006) and high-grade colitis (22.5 vs. 2.47, p = 0.021) with ipilimumab as compared to PD-1/PD-L1 drugs. Here, CD274 is linked to colitis.